Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jun 27, 2012 (14 years ago)

Carboplatin Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

The affected lots of Carboplatin Injection, Cytarabine Injection, Methotrexate Injection, USP, and Paclitaxel Injection are beig recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Carboplatin Injection, 10 mg/mL, 45 mL Multi-Dose Vial, Rx only, antineoplastic/cytotoxic agent; Manufactured for Hospira, Inc., Lake Forest, IL 60045, Product of Australia, NDC 61703-339-50 (Hospira label), NDC 61703-360-50 (Novoplus label)

Affected NDCs 61703-0339-50 61703-0360-50

Compare with the code on your package — it is the most precise check available.

Drug: Carboplatin

Product details

From the FDA NDC directory, for the product codes this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Carboplatin
NDC 61703-0339
10 mg/mL Injection, Solution
Intravenous
Hospira, Inc. Rx
Carboplatin
NDC 61703-0360
10 mg/mL Injection, Solution
Intravenous
Hospira, Inc. Rx
Recalling firm
Hospira Inc.
NDC code
61703-339-50
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1679-2012 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Carboplatin recalls

See all
Class II · Moderate risk

Carboplatin active pharmaceutical ingredient packaged in varying…

Penicillin Cross Contamination: All lots of all products repackaged between 01/05/12 through 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-562-2015
Class II · Moderate risk

CARBOplatin Injection

Lack of Assurance of Sterility: The required reduction of endotoxin was not met during the annual revalidation of the vial washer.

Terminated Sterility / contamination Teva Pharmaceuticals USA, Inc. NDC 0703-3249-11 D-928-2013
Class I · High risk

Carboplatin Injection

Crystallization: Product is being recalled due to visible particulates identified during a retain sample inspection. Findings have identified the particles as Carboplatin crystals.

Completed Failed specification Hospira Inc. NDC 61703-339-50 D-154-2013

Other recalls by Hospira Inc.

All 2012 recalls
Class II · Moderate risk

DOBUTamine Injection

Discoloration: Firm received complaints of product discoloration and particulates.

Terminated Failed specification Hospira Inc. NDC 0409-2025-20 D-1500-2016